More reads

• Health care may not be the stock haven it once was. (Bloomberg)
• Novartis delayed reveal of bad data for $2.1 million gene therapy. Now patients and pharma suffer. (Forbes)
• AstraZeneca’s Farxiga gets the jump on Jardiance. (EP Vantage)